Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Merck
Mallinckrodt
Dow

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for ONC201


Email this page to a colleague

« Back to Dashboard

What is the drug development status for ONC201?

ONC201 is an investigational drug.

There have been 23 clinical trials for ONC201. The most recent clinical trial was a Phase 2 trial, which was initiated on October 31st 2017.

The most common disease conditions in clinical trials are Glioma, Glioblastoma, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Oncoceutics, Inc., Chimerix, and National Cancer Institute (NCI).

There are fourteen US patents protecting this investigational drug and one hundred and forty-one international patents.

Recent Clinical Trials for ONC201
TitleSponsorPhase
Combination Therapy for the Treatment of Diffuse Midline GliomasMithil Prasad FoundationPhase 2
Combination Therapy for the Treatment of Diffuse Midline GliomasStorm the Heavens FundPhase 2
Combination Therapy for the Treatment of Diffuse Midline GliomasThe Chad-Tough Defeat DIPG FoundationPhase 2

See all ONC201 clinical trials

Clinical Trial Summary for ONC201

Top disease conditions for ONC201
Top clinical trial sponsors for ONC201

See all ONC201 clinical trials

US Patents for ONC201

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ONC201 ⤷  Try it Free 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) ⤷  Try it Free
ONC201 ⤷  Try it Free Imipridones for gliomas Oncoceutics, Inc. (Philadelphia, PA) ⤷  Try it Free
ONC201 ⤷  Try it Free 7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy Oncoceutics, Inc. (Philadelphia, PA) ⤷  Try it Free
ONC201 ⤷  Try it Free Imipridones for gliomas Oncoceutics, Inc. (Philadelphia, PA) ⤷  Try it Free
ONC201 ⤷  Try it Free 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]- pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ONC201

Drugname Country Document Number Estimated Expiration Related US Patent
ONC201 Australia AU2014244117 2033-03-13 ⤷  Try it Free
ONC201 Australia AU2014349150 2033-03-13 ⤷  Try it Free
ONC201 Australia AU2019201896 2033-03-13 ⤷  Try it Free
ONC201 Australia AU2020200875 2033-03-13 ⤷  Try it Free
ONC201 Australia AU2020233606 2033-03-13 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Merck
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.